PURPOSE: The association of deficient DNA mismatch repair (dMMR) with prognosis in patients with colon cancer treated withadjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy remains unknown. PATIENTS AND METHODS: Resected, stage III colon carcinomas from patients (N = 2,686) randomly assigned toFOLFOX ± cetuximab (North Central Cancer Treatment Group N0147 trial) were analyzed for mismatch repair (MMR) protein expression and mutations in BRAF(V600E) (exon 15) and KRAS (codons 12 and 13). Association of biomarkers with disease-free survival (DFS) was determined using Cox models. A validation cohort (Cancer and Leukemia Group B 88903 trial) was used. RESULTS:dMMR was detected in 314 (12%) of 2,580 tumors, of which 49.3% and 10.6% had BRAF(V600E) or KRAS mutations, respectively. MMR status was not prognostic overall (adjusted hazard ratio [HR], 0.82; 95% CI, 0.64 to 1.07; P = .14), yet significant interactions were found between MMR and primary tumor site (P(interaction) = .009) and lymph node category (N1 v N2; P(interaction) = .014). Favorable DFS was observed for dMMR versus proficient MMR proximal tumors (HR, 0.71; 95% CI, 0.53 to 0.94; P = .018) but not dMMR distal tumors (HR, 1.71; 95% CI, 0.99 to 2.95; P = .056), adjusting for mutations and covariates. Any survival benefit of dMMR was lost in N2 tumors. Mutations in BRAF(V600E) (HR, 1.37; 95% CI, 1.08 to 1.70; P = .009) or KRAS (HR, 1.44; 95% CI, 1.21 to 1.70; P < .001) were independently associated with worse DFS. The observed MMR by tumor site interaction was validated in an independent cohort of stage III colon cancers (P(interaction) = .037). CONCLUSION: The prognostic impact of MMR depended on tumor site, and this interaction was validated in an independent cohort. Among dMMR cancers, proximal tumors had favorable outcome, whereas distal or N2 tumors had poor outcome. BRAF or KRAS mutations were independently associated with adverse outcome.
RCT Entities:
PURPOSE: The association of deficient DNA mismatch repair (dMMR) with prognosis in patients with colon cancer treated with adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy remains unknown. PATIENTS AND METHODS: Resected, stage III colon carcinomas from patients (N = 2,686) randomly assigned to FOLFOX ± cetuximab (North Central Cancer Treatment Group N0147 trial) were analyzed for mismatch repair (MMR) protein expression and mutations in BRAF(V600E) (exon 15) and KRAS (codons 12 and 13). Association of biomarkers with disease-free survival (DFS) was determined using Cox models. A validation cohort (Cancer and Leukemia Group B 88903 trial) was used. RESULTS: dMMR was detected in 314 (12%) of 2,580 tumors, of which 49.3% and 10.6% had BRAF(V600E) or KRAS mutations, respectively. MMR status was not prognostic overall (adjusted hazard ratio [HR], 0.82; 95% CI, 0.64 to 1.07; P = .14), yet significant interactions were found between MMR and primary tumor site (P(interaction) = .009) and lymph node category (N1 v N2; P(interaction) = .014). Favorable DFS was observed for dMMR versus proficient MMR proximal tumors (HR, 0.71; 95% CI, 0.53 to 0.94; P = .018) but not dMMR distal tumors (HR, 1.71; 95% CI, 0.99 to 2.95; P = .056), adjusting for mutations and covariates. Any survival benefit of dMMR was lost in N2 tumors. Mutations in BRAF(V600E) (HR, 1.37; 95% CI, 1.08 to 1.70; P = .009) or KRAS (HR, 1.44; 95% CI, 1.21 to 1.70; P < .001) were independently associated with worse DFS. The observed MMR by tumor site interaction was validated in an independent cohort of stage III colon cancers (P(interaction) = .037). CONCLUSION: The prognostic impact of MMR depended on tumor site, and this interaction was validated in an independent cohort. Among dMMR cancers, proximal tumors had favorable outcome, whereas distal or N2 tumors had poor outcome. BRAF or KRAS mutations were independently associated with adverse outcome.
Authors: Shuji Ogino; Kaori Shima; Jeffrey A Meyerhardt; Nadine J McCleary; Kimmie Ng; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Donna Spiegelman; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs Journal: Clin Cancer Res Date: 2011-12-06 Impact factor: 12.531
Authors: R Gryfe; H Kim; E T Hsieh; M D Aronson; E J Holowaty; S B Bull; M Redston; S Gallinger Journal: N Engl J Med Date: 2000-01-13 Impact factor: 91.245
Authors: Steven R Alberts; Daniel J Sargent; Suresh Nair; Michelle R Mahoney; Margaret Mooney; Stephen N Thibodeau; Thomas C Smyrk; Frank A Sinicrope; Emily Chan; Sharlene Gill; Morton S Kahlenberg; Anthony F Shields; James T Quesenberry; Thomas A Webb; Gist H Farr; Barbara A Pockaj; Axel Grothey; Richard M Goldberg Journal: JAMA Date: 2012-04-04 Impact factor: 56.272
Authors: Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman Journal: CA Cancer J Clin Date: 2011-02-04 Impact factor: 508.702
Authors: Gordon Hutchins; Katie Southward; Kelly Handley; Laura Magill; Claire Beaumont; Jens Stahlschmidt; Susan Richman; Philip Chambers; Matthew Seymour; David Kerr; Richard Gray; Philip Quirke Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: Frank A Sinicrope; Nathan R Foster; Stephen N Thibodeau; Silvia Marsoni; Genevieve Monges; Roberto Labianca; George P Kim; Greg Yothers; Carmen Allegra; Malcolm J Moore; Steven Gallinger; Daniel J Sargent Journal: J Natl Cancer Inst Date: 2011-05-19 Impact factor: 13.506
Authors: Patrick G Gavin; Linda H Colangelo; Debora Fumagalli; Noriko Tanaka; Matthew Y Remillard; Greg Yothers; Chungyeul Kim; Yusuke Taniyama; Seung Il Kim; Hyun Joo Choi; Nicole L Blackmon; Corey Lipchik; Nicholas J Petrelli; Michael J O'Connell; Norman Wolmark; Soonmyung Paik; Kay L Pogue-Geile Journal: Clin Cancer Res Date: 2012-10-08 Impact factor: 12.531
Authors: Arnaud D Roth; Mauro Delorenzi; Sabine Tejpar; Pu Yan; Dirk Klingbiel; Roberto Fiocca; Giovanni d'Ario; Laura Cisar; Roberto Labianca; David Cunningham; Bernard Nordlinger; Fred Bosman; Eric Van Cutsem Journal: J Natl Cancer Inst Date: 2012-10-25 Impact factor: 13.506
Authors: Harry H Yoon; David Tougeron; Qian Shi; Steven R Alberts; Michelle R Mahoney; Garth D Nelson; Suresh G Nair; Stephen N Thibodeau; Richard M Goldberg; Daniel J Sargent; Frank A Sinicrope Journal: Clin Cancer Res Date: 2014-03-31 Impact factor: 12.531
Authors: Daniel A Sussman; Monique N Hernandez; Stacey L Tannenbaum; Judith M Bonner; L A McClure; D J Lee Journal: Am J Gastroenterol Date: 2015-01 Impact factor: 10.864
Authors: Jennifer B Goldstein; William Wu; Ester Borras; Gita Masand; Amanda Cuddy; Maureen E Mork; Sarah A Bannon; Patrick M Lynch; Miguel Rodriguez-Bigas; Melissa W Taggart; Ji Wu; Paul Scheet; Scott Kopetz; Y Nancy You; Eduardo Vilar Journal: Clin Cancer Res Date: 2017-05-18 Impact factor: 12.531
Authors: Frank A Sinicrope; Michelle R Mahoney; Harry H Yoon; Thomas C Smyrk; Stephen N Thibodeau; Richard M Goldberg; Garth D Nelson; Daniel J Sargent; Steven R Alberts Journal: Clin Cancer Res Date: 2015-07-17 Impact factor: 12.531